Abstract:As the mutant estrogen receptor (ER) continues to be characterized, breast cancer is becoming increasingly difficult to cure when treated with hormone therapy. In this regard, a strategy to selectively and effectively degrade the ER might be an effective alternative to endocrine therapy for breast cancer. In a previous study, we identified a novel series of 7-oxabicyclo[2.2.1]heptene sulfonamide (OBHSA) compounds as full ER antagonists while lacking the prototypical ligand side chain that has been widely used to induce antagonism of ERα. Further crystal structure studies and phenotypic assays revealed that these compounds are selective estrogen receptor degraders (SERDs) with a new mechanism of action. However, from a drug discovery point of view, there still is room to improve the potency of these OBHSA compounds. In this study, we have developed new classes of SERDs that contain the OBHSA core structure and different side chains, e.g., basic side chains, long alkyl acid side chains, and glycerol ether side chains, to simply mimic the degrons of proteolysis targeting chimera (PROTAC) and then investigated the structure-activity relationships of these PROTAC-like hybrid compounds. These novel SERDs could effectively inhibit MCF-7 cell proliferation and demonstrated good ERα degradation efficacy. Among the SERDs, compounds 17d, 17e and 17g containing a basic side chain with a N-trifluoroethyl substituent and a para methoxyl group at the phenyl group of the sulfonamide turned out to be the best candidates for ER degraders. A further docking study of these compounds with ERα elucidates their structure-activity relationships, which provides guidance to design new PROTAC degrons targeting ER for breast cancer therapy. Lastly, easy modification of these PROTAC-like SERDs enables further fine-tuning of their pharmacokinetic properties, including oral availability.

Identification of Novel Dual-Target Estrogen Receptor Α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer

Structure-guided Identification of Novel Dual-Targeting Estrogen Receptor Α Degraders with Aromatase Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer

Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer

Dual-target Inhibitors Based on ERα: Novel Therapeutic Approaches for Endocrine Resistant Breast Cancer

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer

Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: an Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators Against Endocrine-Resistant Breast Cancer.

Discovery of a Novel Class of PROTACs As Potent and Selective Estrogen Receptor Α Degraders to Overcome Endocrine-Resistant Breast Cancer in Vitro and in Vivo

Design, Synthesis and Biological Evaluation of Novel Dual-Acting Modulators Targeting Both Estrogen Receptor Α (erα) and Lysine-Specific Demethylase 1 (LSD1) for Treatment of Breast Cancer.

Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy

Structural Optimization of Tetrahydroisoquinoline-Hydroxamate Hybrids As Potent Dual ERα Degraders and HDAC Inhibitors.

Novel 11Β-Substituted Estradiol Conjugates: Transition from ERα Agonizts to Effective PROTAC Degraders

Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.

Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer

Design, Synthesis and Evaluation of 6-Aryl-indenoisoquinolone Derivatives Dual Targeting ERα and VEGFR-2 As Anti-Breast Cancer Agents.

A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway

Exploring the PROTAC Degron Candidates: OBHSA with Different Side Chains As Novel Selective Estrogen Receptor Degraders (Serds)

Discovery of Thieno[2,3-e]indazole Derivatives As Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability

X-ray Crystallography Study and Optimization of Novel Benzothiophene Analogs As Potent Selective Estrogen Receptor Covalent Antagonists (sercas) with Improved Potency and Safety Profiles.

New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2h,4h)-dione Analogues: Development of Potent Eef2k Degraders Against Triple-Negative Breast Cancer.

Development of Novel Tetrahydroisoquinoline-Hydroxamate Conjugates As Potent Dual SERDs/HDAC Inhibitors for the Treatment of Breast Cancer